Unicancer — Sponsor Intelligence | 63 EU Trials

Filter these 63 trials by condition, phase, country and more.

Open in Search →

63 Registered trials

31 Recruiting

27 Completed trials

12 Countries active

91 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 25 Phase II/III: 1 Phase II: 36 Other: 1

Oversight events:

1 temporary halt 1 corrective measure across 2 trials

View oversight register →

100%

27 of 27 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Prostate cancer 3 Triple negative breast cancer 3 Breast cancer 2 Head and neck cancer 2 Bladder cancer 2 Ewing´s sarcoma metastatic 1 HER2 positive colorectal cancer 1 Non-small cell lung cancer metastatic 1 Prostate cancer metastatic 1 Soft tissue sarcoma 1 Biliary cancer metastatic 1 Breast cancer stage I 1

Top IMPs

DURVALUMAB 7 DAROLUTAMIDE 4 PEMBROLIZUMAB 4 ATEZOLIZUMAB 2 BINIMETINIB 2 CAPECITABINE 2 DOXORUBICIN HYDROCHLORIDE 2 ENCORAFENIB 2 FULVESTRANT 2 IVONESCIMAB 2 TRASTUZUMAB 2 TRIFLURIDINE, TIPIRACIL 2

All trials — page 2

63 total

Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Phase III 4 countries DAROLUTAMIDE
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Phase III 6 countries GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting

2023-505298-34-00 Phase II 1 country DOSTARLIMAB
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Phase III 2 countries BINIMETINIB; DURVALUMAB; ENCORAFENIB; FUTIBATINIB; NERATINIB; NIRAPARIB; TRASTUZ…
Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting

2022-502351-60-00 Phase II 1 country CAPECITABINE; TRASTUZUMAB; TUCATINIB
Testing immunotherapy for patients with liver cancer and moderatelyaltered liver functions Recruiting

2024-516443-57-00 Phase II 1 country TISLELIZUMAB
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Phase II 1 country TRIFLURIDINE, TIPIRACIL; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Phase III 10 countries DAROLUTAMIDE
Comparison of Cyclophosphamide and doxorubicin as a first line treatment in elderly patients with metastatic sarcoma Recruiting

2024-510653-10-00 Phase III 1 country
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Phase III 1 country
Atezolizumab After Chemo-radiotherapy for muscle-invasive bladder cancer Patients Not Eligible for Radical Cystectomy Recruiting

2024-512002-26-00 Phase II 1 country ATEZOLIZUMAB
Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r… Recruiting

2024-514780-26-00 Phase II 1 country MIFAMURTIDE
Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma… Recruiting

2024-512827-36-00 Phase II 1 country
Evaluation of the effectiveness of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. Recruiting

2024-518002-41-00 Phase II 1 country DURVALUMAB
Hyperthermic Intraperitoneal Chemotherapy in the treatment of Ovarian Cancer relapse Recruiting

2024-517390-24-00 Phase III 1 country
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Phase III 2 countries SACITUZUMAB GOVITECAN
Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi… Ended

2024-512224-11-00 Phase II 1 country DURVALUMAB
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Phase II 1 country
Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain Ended

2023-505302-42-00 Phase II 1 country BINIMETINIB; ENCORAFENIB; PEMBROLIZUMAB
Multi-drug treatment for breast cancer patients with brain metastases Ended

2024-510703-11-00 Phase II 1 country TUCATINIB
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Phase III 1 country ABEMACICLIB
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 Phase III 1 country APALUTAMIDE
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 Phase II 3 countries DURVALUMAB; FULVESTRANT; GOSERELIN ACETATE; OLAPARIB
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended

2024-512165-13-00 Phase II 1 country DURVALUMAB

Showing 25–48 of 63 trials

← All sponsors A–Z